PLoS ONE, 2021 Ebola virus (EBOV), a member of the mononegaviral family Filoviridae, causes severe disease associated with high lethality in humans. Despite enormous progress in development of EBOV medical countermeasures, no anti-EBOV treatment has been approved.
Yingyun Cai +5 more
doaj +2 more sources
Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin
OncoImmunology, 2019 Granulysin is a protein present in the granules of human cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, with cytolytic activity against microbes and tumors.
Rocio Navarro +2 more
exaly +2 more sources
Comparison of two immunotoxins against DLL3 receptor; as an inhibitor for small cell lung cancer [PDF]
Frontiers in Molecular BiosciencesDespite the efforts of researchers to develop new treatments for small cell lung cancer (SCLC), achieving effective treatment has not yet happened. Targeted therapy utilizing delta-like ligand 3 (DLL3), which is highly expressed in SCLC patients, holds ...
Mohammad Hossein Ataee +4 more
doaj +2 more sources
Integrated bioprocessing and genetic strategies to enhance soluble expression of anti-HER2 immunotoxin in E. Coli [PDF]
AMB ExpressImmunotoxins are widely applied for cancer therapy. However, bacterial expression of immunotoxins usually leads to the formation of insoluble and non-functional recombinant proteins. This study was aimed to improve soluble expression of a novel anti-HER2
Sheida Mani +3 more
doaj +2 more sources
Bacterial Protein Toxins as Anticancer Agents: Clinical Potential of Pseudomonas and Anthrax Toxins [PDF]
ToxinsProtein toxins are biologically active polypeptides produced by a variety of organisms, including bacteria, plants, fungi, and animals. These molecules exert potent and specific toxic effects on target cells and are primarily associated with ...
Richa Misra +6 more
doaj +2 more sources
Unlocking the potential of engineered microbes in immunotoxin-based cancer therapy [PDF]
Frontiers in MicrobiologyImmunotoxins (ITs), as targeted cancer therapies, confront limitations including off-target effects, immunogenicity, and inadequate tumor penetration, hindering clinical translation.
Quan Wang +10 more
doaj +2 more sources
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers
Toxins, 2016 Many epithelial cancers rely on enhanced expression of the epidermal growth factor receptor (EGFR) to drive proliferation and survival pathways. Development of therapeutics to target EGFR signaling has been of high importance, and multiple examples have ...
David Fitzgerald
exaly +3 more sources
Production and Verification of Anti-Tumor Activity of Monoclonal Anti-EGFR-Recombinant PE38 Immunotoxin in A431 Tumor Cells [PDF]
ImmunoAnalysis, 2021 Background: Tumor growth and progression depend largely on the activity of cell membrane receptors like epidermal growth factor receptor (EGFR). This receptor plays a significant role in the growth and survival of many solid tumors.
Khalil Hajiasgharzadeh +2 more
doaj +1 more source
In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin [PDF]
Iranian Journal of Basic Medical Sciences, 2022 Objective(s): A variety of signaling molecules have been identified that play a role in angiogenesis, of prime importance, vascular endothelial growth factor (VEGF) and its resceptor (VEGFR), which is highly expressed in most human solid tumors ...
Mohammad Hosseininejad-Chafi +9 more
doaj +1 more source
Engineering and production of recombinant bovine pancreatic ribonuclease enzyme (RNase A) as a potential therapeutic [PDF]
مجله بیوتکنولوژی کشاورزی, 2021 Objective Immunotoxins are one of the most promising ways in therapeutic fields, specially cancer therapy which have a unique toxin-antibody structure, and kill the cancer cell by passing through the cell membrane and entering the target cell.
Masoume Vakili-Azghandi +3 more
doaj +1 more source